Evidence map›Paper›PMID 28484844›Full record

Trial reportJournal of cancer research and clinical oncology2017

Urinary transcript quantitation of CK20 and IGF2 for the non-invasive bladder cancer detection.

Karsten Salomo, Doreen Huebner, Manja U Boehme, Alexander Herr, Werner Brabetz, Ulrike Heberling, Oliver W Hakenberg, Daniela Jahn, Marc-Oliver Grimm, Daniel Steinbach and 4 more

Open access · greenAbstract readClinical TrialValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of cancer research and clinical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. The Role of Novel Bladder Cancer Diagnostic and Surveillance Biomarkers-What Should a Urologist Really Know?International journal of environmental research and public health · 2022
    Review
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Karsten SalomoDepartment of Urology, Technische Universität Dresden, Fetscherstr. 74, 01307, Dresden, Germany. Karsten.Salomo@uniklinikum-dresden.de.ORCID http://orcid.org/0000-0001-7562-289X
Doreen HuebnerDepartment of Urology, Technische Universität Dresden, Fetscherstr. 74, 01307, Dresden, Germany.
Manja U BoehmeBiotype Diagnostic GmbH, Dresden, Germany.
Alexander HerrBiotype Diagnostic GmbH, Dresden, Germany.
Werner BrabetzBiotype Diagnostic GmbH, Dresden, Germany.
Ulrike HeberlingDepartment of Urology, Technische Universität Dresden, Fetscherstr. 74, 01307, Dresden, Germany.
Oliver W HakenbergDepartment of Urology, University of Rostock, Rostock, Germany.
Daniela JahnDepartment of Urology, University of Rostock, Rostock, Germany.
Marc-Oliver GrimmDepartment of Urology, Jena University Hospital, Jena, Germany.
Daniel SteinbachDepartment of Urology, Jena University Hospital, Jena, Germany.
Marcus HorstmannDepartment of Urology, Malteser Hospital St. Josefshospital, Krefeld, Germany.
Michael FroehnerDepartment of Urology, Technische Universität Dresden, Fetscherstr. 74, 01307, Dresden, Germany.
Manfred P WirthDepartment of Urology, Technische Universität Dresden, Fetscherstr. 74, 01307, Dresden, Germany.
Susanne FuesselDepartment of Urology, Technische Universität Dresden, Fetscherstr. 74, 01307, Dresden, Germany.
Technische Universität Dresden · DEJena University Hospital · DEUniversity of Rostock · DEKlinik und Poliklinik für Psychotherapie und Psychosomatik · DEMalteser-Krankenhaus · DE

Funding

European Regional Development Fund 100095690
6 · The paper itself

Abstract

purposeCytokeratin 20 (CK20) and insulin-like growth factor 2 (IGF2) were previously proposed to be elevated in clinical samples from patients with bladder cancer (BCa). A two cohort design validation study was used to assess the relevance for BCa detection by transcript quantitation of both markers in urine samples. Their diagnostic value was assessed in comparison with voided urine cytology (VUC).

methodsRNA isolation was carried out using cellular sediments of urine samples from 196/103 histologically positive BCa patients, as well as 97/50 control subjects for the test (TC) and validation cohort (VC), respectively. Urinary transcript levels of CK20 and IGF2 were determined by qPCR.

resultsRelative transcript levels were significantly elevated 3.4/11-fold for CK20 and 188/64-fold for IGF2 (p < 0.001) in urine sediments of BCa patients compared to controls in the TC and VC, respectively. In a combined analysis, the resulting sensitivity (SN) (SN

conclusionsTranscript levels of IGF2 and CK20 enabled the detection of BCa with a diagnostic performance similar to VUC. Combined analysis of voided urine cytology together with altered transcript levels of CK20 and IGF2 enhanced sensitivity, but did not improve overall test performance.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, Transitional CellCohort StudiesFemaleHumansInsulin-Like Growth Factor IIKeratin-20MaleMiddle AgedSensitivity and SpecificityUrinary Bladder NeoplasmsBiomarkers, TumorIGF2 protein, humanInsulin-Like Growth Factor IIKeratin-20KRT20 protein, humanCytokeratin 20Insulin-like growth factor IIKRT20Tumor markerUrineUrothelial carcinoma

Identifiers

PMID28484844
PMCPMC11818997
OpenAlexW2612492370

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.